CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
July 06, 2022 16:05 ET
|
CytomX Therapeutics Inc.
- Study meets primary endpoint of objective response rate in HR+/HER2-non-amplified breast cancer - - Secondary endpoints including clinical benefit rate at 24 weeks and median progression-free...
CytomX Therapeutics Announces New Employment Inducement Grants
June 16, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
June 01, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced...
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors
May 26, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022 16:15 ET
|
CytomX Therapeutics Inc.
- Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for second half of 2022 - - Phase 2 expansion...
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
April 28, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
April 14, 2022 16:15 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
March 23, 2022 16:15 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
March 17, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
March 01, 2022 16:15 ET
|
CytomX Therapeutics Inc.
- Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 - - First-in-human study of CX-904 in advanced solid tumors to be...